Enliven Therapeutics (ELVN) Free Cash Flow (2019 - 2026)

Enliven Therapeutics has disclosed Free Cash Flow across 8 years of filings, most recently posting -$19.3 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$19.3 million, up 20.11% year-over-year; the trailing twelve-month figure through Mar 2026 was -$65.6 million (up 11.35% YoY), and the FY2025 annual result was -$70.5 million, up 3.79% from the prior year.
• Free Cash Flow came in at -$19.3 million for Q1 2026 at Enliven Therapeutics, down from -$15.8 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$6.5 million in Q3 2022 to a low of -$24.1 million in Q1 2025.
• The 5-year median for Free Cash Flow is -$15.8 million (2025), against an average of -$15.1 million.
• Across the five-year window, Free Cash Flow soared 40.73% in 2022 and slumped 148.09% in 2023, its largest moves.
• Enliven Therapeutics' Free Cash Flow stood at -$8.2 million in 2022, then sank by 51.54% to -$12.5 million in 2023, then plunged by 37.67% to -$17.2 million in 2024, then increased by 7.93% to -$15.8 million in 2025, then decreased by 21.8% to -$19.3 million in 2026.
• The last three Free Cash Flow figures came in at -$19.3 million (Q1 2026), -$15.8 million (Q4 2025), and -$13.4 million (Q3 2025), per Business Quant data.